lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Sudetenland as part of Germany === The Sudetenland was initially put under military administration, with General Wilhelm Keitel as military governor. On 14 April 1939, the annexed territories were divided, with the southern parts being incorporated into the neighbouring Reichsgaue of Niederdonau, Oberdonau and Bayerische Ostmark.
For convenience, three different views of the data are available on Wikipedia: two sets of "segmented tables", and a single "unitized table (all elements)". The unitized table allows easy visualization of proton/neutron-count trends but requires simultaneous horizontal and vertical scrolling. The segmented tables permit easier examination of a particular chemical element with much less scrolling. Links are provided to quickly jump between the different sections.
=== Gene therapy prior to conception === Mitochondrial replacement therapy (MRT), where the nuclear DNA is transferred to another healthy egg cell leaving the defective mitochondrial DNA behind, is an IVF treatment procedure. Using a similar pronuclear transfer technique, researchers at Newcastle University led by Douglass Turnbull successfully transplanted healthy DNA in human eggs from women with mitochondrial disease into the eggs of women donors who were unaffected. In such cases, ethical questions have been raised regarding biological motherhood, since the child receives genes and gene regulatory molecules from two different women. Using genetic engineering in attempts to produce babies free of mitochondrial disease is controversial in some circles and raises important ethical issues. A male baby was born in Mexico in 2016 from a mother with Leigh syndrome using MRT. In September 2012 a public consultation was launched in the UK to explore the ethical issues involved. Human genetic engineering was used on a small scale to allow infertile women with genetic defects in their mitochondria to have children. In June 2013, the United Kingdom government agreed to develop legislation that would legalize the 'three-person IVF' procedure as a treatment to fix or eliminate mitochondrial diseases that are passed on from mother to child. The procedure could be offered from 29 October 2015 once regulations had been established.
The synthesis of ansamycin antibiotic (+)-mycotrienol makes use of a late stage tandem Stille type macrocycle coupling. Here, the organostannane has two terminal tributyl tin groups attacked to an alkene. This organostannane "stitches" the two ends of the linear starting material into a macrocycle, adding the missing two methylene units in the process. After oxidation of the aromatic core with ceric ammonium nitrate (CAN) and deprotection with hydrofluoric acid yields the natural product in 54% yield for the 3 steps. An alkene group is added to vinyl bromide, followed by an in situ Diels-Alder cycloaddition between the added alkene and the alkene in the pyrrolidine ring.
Sources: en.wikipedia.org
Eye exposure: 18 mg (0.28 gr)/6 hours (rabbit) Oral: 72 mg/kg (0.00115 oz/lb) (rat, LD50), 1,186 mg/kg (0.01898 oz/lb) (rat, TDLo), 5,112 mg/kg (0.08179 oz/lb) (rat, TD) Inhalation: 12,500 ppm (human, TCLo), 960 ppm/4 hours (dog, LC50) 33–50 ppm (rat or mouse, TC), 800 ppm/4 hours (rat or mouse, LC50) Subcutaneous injection: 100 mg/kg (0.0016 oz/lb) (cat, LDLo), 292 mg/kg (0.00467 oz/lb) (mouse, TDLo) 900–2,600 mg/kg (0.014–0.042 oz/lb) (mouse, TD), 187 mg/kg (0.00299 oz/lb) (rat, LD50). Intraperitoneal injection: 750 mg/kg (0.0120 oz/lb) (mouse, TDLo), 175 mg/kg (0.00280 oz/lb) (mouse, LD50) Intravenous injection: 175 mg/kg (0.00280 oz/lb) (rabbit, LD50), 290 mg/kg (0.0046 oz/lb) (mouse, LD50) The US Environmental Protection Agency (USEPA) estimated in 2016 that for low doses, the inhalation of ethylene oxide for a lifetime could increase an individual's lifetime cancer risk by as much as 3.0 × 10−3 per μg/m3 (without considering that early-life exposures are likely more potent). The USEPA estimated the slope of the dose-response declines at higher doses, and extra cancer risk estimates for several occupational exposure scenarios are calculated.
Maurice Peston, Baron Peston (19 March 1931 – 23 April 2016) economist and Labour life peer; author of numerous scholarly academic texts and monographs on economics; research interests included macroeconomic policy and the economics of education; father of Robert Peston. Adam Phillips (psychologist)(born 19 September 1954) is a British psychoanalytic psychotherapist, essayist and author of well over twenty books, scholarly articles and academic papers; since 2003 he has been the general editor of the new Penguin Modern Classics translations of Sigmund Freud and is a regular contributor to the London Review of Books. Alexander Piatigorsky, writer, philosopher, culture theorist; winner of the 2002 Russian Bely Prize for literature Irma Brenman Pick (13 April 1934 – 3 August 2023) South African Latvian Jewish British psychologist and psychoanalyst known for her work on countertransference. She served as the president of the British Psychoanalytical Society from 1997 to 2000. Daniel Pick (born 1960); historian, psychoanalyst, university teacher, writer, broadcaster; was recipient of a senior Investigator grant from the Wellcome Trust and led research group at Birkbeck exploring history of the human sciences and 'psy' professions during the Cold War; project entitled 'Hidden Persuaders': Brainwashing, Culture, Clinical Knowledge and the Cold War Human Sciences, c. 1950–1990'; was fellow and training analyst of the British Psychoanalytical Society and author of numerous articles and several books on modern cultural history, psychoanalysis, and history of the human sciences.
== Interpretation == If the positive or negative controls fail, than the entire testing procedure is invalid and must be repeated. Criteria for a positive MMA will vary by laboratory, though the originally established threshold set by Sandra Nance et al., is >20% phagocytic activity observed. Clinically, a positive MMA would indicate that the patient's serum used in the assay contains clinically significant antibodies that are capable of causing antibody-mediated phagocytosis.
Noroxycodone is the major metabolite of the opioid analgesic oxycodone. It is formed from oxycodone in the liver via N-demethylation predominantly by CYP3A4. Noroxycodone binds to and activates the μ-opioid receptor (MOR) similarly to oxycodone, although with one-third of the affinity of oxycodone and 5- to 10-fold lower activational potency. However, although a potent MOR agonist, noroxycodone poorly crosses the blood-brain-barrier into the central nervous system, and for this reason, is only minimally analgesic in comparison.
==== Metabolism ==== Ritonavir is extensively metabolized by the liver, driven predominantly by the CYP3A enzyme family, with minor contributions from CYP2D6. The biotransformation yields four major metabolites via pathways including N-demethylation, hydroxylation of the isopropyl side chain, and cleavage of the terminal thiazole groups. The primary metabolite is the isopropylthiazole oxidation metabolite (M-2), which retains antiviral activity comparable to the parent drug but circulates at very low plasma concentrations.
Sources: en.wikipedia.org
== Humphreys' influence == Humphreys influenced generations of sociologists and other social and behavioral scientists in complex ways. He is often studied in research methods classes for the ethical questions that his works raised. However, Earl Babbie, who writes about sociological research methods, notes that the controversy about "sociological snoopers" and research ethics was likely the result of societal homophobia and disgust with the research topic, and not due to real problems with research methods. Schacht credits Humphreys with pioneering research on impersonal sex, now a common topic of research and advocacy in the context of HIV/AIDS. Tewksbury writes about the multiple studies that were inspired by Humphrey's work, calling his work a rich legacy for future sex researchers. According to Brekhus, Humphrey's contribution to sociological theory, in particular to the development of the concept of identity politics, is often overlooked, but should be hailed as an important forerunner to modern queer theory. Nardi also lauds Humphreys' theoretical work, especially his concept of the breastplate of righteousness. Humphreys developed this idea to explain the apparent contradiction of presumably straight, married men holding a public conservative stance against homosexuality, yet engaging in impersonal sex with men in public settings. In 2003, the presidential session at the Society for the Study of Social Problems (SSSP) was devoted to honoring Humphrey's pioneering work on sexuality.
==== Liquid crystal microcapsules ==== Fabrication of liquid crystals has been a point of intrigue for over 5 decades for their anisotropic properties. Microfluidic devices can be used for the synthesis of confined cholesteric liquid crystals through layering of multiple shell-like layers consisting of varying oil-in-water and water-in-oil emulsions. The construction of encapsulated liquid crystals through microfluidic flow of liquid crystal droplets in an immiscible oil allows for monodispersed emulsion layer thickness and composition previously unseen before the advent of microfluidic techniques. The advent of liquid crystal technology has led to advancements in optical displays used both in research and consumer branded products, but more recent discoveries have opened the door to the combination of photon combination and upconversion as well as optical sensors for biological analytes.
They finished second behind Manchester United however, losing their slender advantage once they lost their penultimate match. United also eliminated Arsenal in a FA Cup semi-final replay after extra time; Wenger afterwards said: "it was a smashing game, and in the end, the luckiest won." In August 1999, Anelka joined Real Madrid, having threatened to strike if Arsenal did not grant him a move abroad. Wenger used a portion of the proceeds generated through the Anelka sale to fund the build of the Arsenal Training Centre, expressing his desire to establish a "home away from Arsenal". He renewed his forward line by signing Davor Šuker from Real Madrid, and Thierry Henry, who joined after seven "injury-interrupted" months at Juventus for £11.5 million. It was Wenger's intention to partner Anelka with Henry, but the former's departure meant the plan was scrapped. The following seasons were comparatively barren. Arsenal again exited the Champions League at the group stage, but dropped down to the UEFA Cup. Wenger guided his team to the final, where they lost to Galatasaray on penalties. In the league, Arsenal finished 18 points behind Manchester United as runners-up, and though they closed the gap to eight points in 2000–01, they never posed a serious title challenge. The trophy drought continued past 2001, when Michael Owen scored two late goals for Liverpool to beat Arsenal in the FA Cup Final. Wenger rued his team's inability to make possession count, but refused to blame individuals, namely Henry, for missing chances.
1955: the Mexican League, previously independent, was classified as Double-A 1961: final season of the Southern Association 1963: the Eastern League and original South Atlantic League were moved from Class A to Double-A 1964: the original South Atlantic League was reconstituted as the Southern League 1967: the Mexican League moved to Triple-A Entering the 2020 minor league season (which was not played, due to the COVID-19 pandemic) the Texas League had been in Double-A since 1946, the Eastern League since 1963, and the Southern League since 1964. Prior to the 2021 season, Major League Baseball (MLB) reorganized the minor leagues. At that time, the existing leagues were temporarily renamed: Eastern League as Double-A Northeast, Southern League as Double-A South, and Texas League as Double-A Central. Following MLB's acquisition of the rights to the names of the historical minor leagues, MLB announced on March 16, 2022, that the leagues would revert to their prior names, effective with the 2022 season.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.